CRVS — Recent News Coverage
All news mentioning CRVS in ESEN's AI-graded feed
News stories with CRVS as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on CRVS. See /coverage/CRVS for the 30-day aggregate.
SEEKINGALPHA.COM
·
2026-08-12
LOW
NEUTRAL
CORR0.32
Corvus: Evaluating Soquelitinib's Science, Market Reach, And Fair Value (NASDAQ:CRVS)
$CRVS
◈ ESEN AI
CRVS is the subject of a valuation analysis focused on soquelitinib's clinical and commercial potential. The article represents a fundamental reassessment of the company's investment thesis rather than disclosure of new…
SEEKINGALPHA.COM
·
2026-08-10
HIGH
BULLISH
CORR0.42
Corvus Stock: Soquelitinib Q1 Interim Futility Analysis AD Drug Advancement (NASDAQ:CRVS)
$CRVS
◈ ESEN AI
Corvus Pharma (CRVS) announced interim futility analysis results for soquelitinib in peripheral T-cell lymphoma (PTCL) and atopic dermatitis (AD), signaling advancement of its clinical pipeline. The futility threshold a…
SEEKINGALPHA.COM
·
2026-08-07
NEUTRAL
NEUTRAL
CORR0.35
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript
$CRVS
◈ ESEN AI
CRVS earnings call transcript publication represents standard quarterly disclosure rather than a material market catalyst. The company's Q2 2026 results communication follows routine reporting cadence, with primary valu…
EXPLORE OTHER FILTERS